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In this issue of Cell, Hill et al. (2005) demonstrate in a mouse model of prostate cancer 
that the tumor cells can initiate and promote expansion of stromal fibroblasts that lack the 
tumor-suppressor protein p53 through a paracrine mechanism. This results in selection of 
highly proliferative fibroblasts associated with the carcinoma that further promote tumor 
progression.Carcinoma (epithelial-derived cancer) 
is the most common type of malignant 
human cancer. It is caused by inherited 
or acquired defects in the regulation of 
normal homeostasis for a given epithe-
lial cell population leading to enhanced 
and often uncontrolled growth at the 
expense of the host. There is good 
evidence to suggest that crosstalk 
between carcinoma epithelial cells and 
adjacent stromal cell populations may 
lead to selection of a tumor microenvi-
ronment that further promotes tumor progression. In human cancer, muta-
tion including loss of heterozygosity 
(LOH) is a common feature associated 
with tumor progression and occurs 
in both the carcinoma epithelium 
and stroma from the tumor microen-
vironment. In this issue of Cell, Hill et 
al. (2005) show in a mouse model of 
prostate carcinoma that tumor cells 
induce upregulation of p53 through a 
paracrine mechanism in stromal fibro-
blasts. This process creates a selec-
tive pressure that promotes the expan-Cell 123, Decsion of a subpopulation of fibroblasts 
that lack p53. Stromal fibroblasts that 
lack p53 then contribute to tumor pro-
gression.
There are many interactions between 
stromal cells and epithelial cells within 
the tumor microenvironment. Several 
recent studies examining stromal fibro-
blast-epithelial cell interactions have 
demonstrated potent interdependent 
regulatory mechanisms necessary to 
maintain nonneoplastic homeostasis. 
Early in the study of stromal fibroblast-Figure 1. The Carcinoma Epithelium Selects for p53 Null Stromal Fibroblasts
Expression of a fragment of the SV40 T antigen (TgAPT121) in the epithelium leads to suppression of retinoblastoma protein family members. Paracrine 
signaling by the epithelium then induces an upregulation in p53 expression in stromal fibroblasts, resulting in decreased fibroblast proliferation. Under this 
selective pressure, fibroblasts that have lost p53 are expanded. These carcinoma-associated fibroblasts contribute to tumor progression and the eventual 
loss of p53 in the epithelium. Multiple changes in stromal fibroblasts are known to contribute to tumor progression, including altered gene expression (for 
example, enhanced expression of SDF-1), loss of heterozygosity (for example, as frequently occur at 11q), and specific mutations (such as those that 
inactivate p53 or PTEN).ember 16, 2005 ©2005 Elsevier Inc. 985
epithelial cell signaling, evidence indi-
cated that carcinomas derived from 
transformed epithelial cells actually 
consisted of malignant epithelium in 
addition to permanently altered stro-
mal fibroblast cell populations, known 
as carcinoma-associated fibroblasts. 
The carcinoma-associated fibroblasts 
were shown to enhance tumorigenesis 
when cocultured with benign hyper-
plastic prostate epithelial cells. These 
early results indicated that fibroblasts 
isolated from primary tumors had 
acquired the ability to promote tumor 
progression in vivo (Hayward et al., 
2001).
Van Dyke and colleagues (Hill et al., 
2005) now use a mouse model of pros-
tate cancer in which the retinoblastoma 
family of proteins are suppressed in the 
prostate epithelium by the expression 
of a fragment of the SV40 T antigen. 
They show that paracrine signaling by 
the epithelium induces upregulation of 
p53 expression in stromal fibroblasts, 
which results in decreased fibroblast 
proliferation (Figure 1). Under this 
selective pressure, fibroblasts that 
have lost p53 are able to expand. Thus, 
it appears that there is a selective evo-
lution of a highly proliferative p53 null 
subpopulation of carcinoma-associ-
ated fibroblasts rather than induction 
of widespread p53 mutation in tumor-
associated fibroblasts.
The p53 tumor-suppressor protein 
is frequently mutated in carcinoma 
cells. The inactivation of p53 can 
occur in the epithelium alone, stroma 
alone, or in both compartments of 
the carcinoma (Kurose et al., 2002). 
The loss of p53 in fibroblasts induces 
tumor progression in adjacent epithe-
lial cell populations (Kiaris et al., 2005). 
Tumors form more rapidly in mice with 
severe combined immunodeficiency 
(SCID) that are injected with human 
mammary adenocarcinoma cells 
when the mice are p53−/− compared 
to p53+/− heterozygous or wild-type 
animals. Moreover, SCID mice that 
are wild-type for p53 develop tumors 
more rapidly when human breast 
cancer cells are mixed with p53 null 
mouse embryonic fibroblasts (MEFs) 
prior to injection than when they are 
mixed with MEFs that are wild-type for 
p53. These results indicate that p53 986 Cell 123, December 16, 2005 ©2005 signaling in the stroma has a role in 
the regulation of tumor progression. 
Similarly, in the prostate cancer model 
used by Hill et al. (2005), loss of p53 
in fibroblasts precedes loss of p53 in 
the epithelium and may contribute to 
tumor progression.
Altered fibroblasts produce fac-
tors that promote tumorigenesis and 
enhance other processes, such as 
angiogenesis, that are required to pro-
mote and sustain cancer progression. 
Recently it was shown that fibroblasts 
isolated from human invasive ductal 
carcinoma can produce stromal cell-
derived factor 1 (SDF-1), a protein that 
both enhances growth of tumor epi-
thelium and promotes angiogenesis 
through the recruitment of endothelial 
cells (Orimo et al., 2005). In addition, 
loss of signaling through the type II 
transforming growth factor β recep-
tor in fibroblasts enhances produc-
tion of soluble factors, such as HGF, 
MSP, and TGF-α, that contribute to 
carcinoma initiation, proliferation, and 
migration while suppressing apopto-
sis in epithelial cells that express the 
respective receptors for these ligands 
(Bhowmick et al., 2004; Cheng et al., 
2005). These studies have helped to 
illustrate the interdependent signal-
ing that controls the stromal-epithelial 
regulation of cancer.
Although the work of Hill et al. (2005) 
helps to explain the high frequency of 
p53 mutations in stromal cells associ-
ated with tumors, it is possible that this 
process could also select for stromal 
cells bearing many other mutations. 
A recent genome analysis of 134 
sporadic invasive breast carcinomas 
revealed that the stromal compo-
nents exhibited a higher number of 
genes preferentially lost due to LOH 
compared to the number lost due to 
LOH in the epithelium (Fukino et al., 
2004). It was reported that 38 markers 
were preferentially lost in the stroma, 
whereas 19 markers were preferen-
tially lost in the epithelium. Because 
many of the markers representing hot 
spots for mutation in the stroma were 
not the same as those identified in the 
epithelium, it is likely that the stromal 
mutations were a result of indepen-
dent mutation rather than divergence 
from a common progenitor (that is, Elsevier Inc.through an epithelial-to-mesenchymal 
transition).
Evidence that genomic instability 
and mutation of individual cell popula-
tions in the tumor microenvironment is 
a regulated process comes from the 
statistical analysis of genomic mark-
ers and direct analysis of deleted 
chromosomal regions from each cell 
population. Mutations observed in the 
11q chromosomal region illustrate how 
LOH can be differentially regulated. Six 
LOH hot-spot markers were identified 
in the 11q region within a 44 Mb span 
that is deleted in the epithelium and is 
flanked by 29 Mb and 11 Mb regions 
that are deleted in the stroma. The 44 
Mbp region deleted in the epithelium 
notably contains the matrix metallo-
proteinase (MMP) gene cluster (Fukino 
et al., 2004). The stage of tumor pro-
gression and distance from the pri-
mary tumor also impact the number of 
LOH events in the stroma (Moinfar et 
al., 2000). Stromal components from 
human breast ductal carcinoma in situ 
exhibit less LOH than stromal com-
ponents within infiltrating ductal car-
cinoma. There is also an association 
between the rate of LOH and the rela-
tive proximity of the stroma to a tumor 
mass (Moinfar et al., 2000). Together, 
these results indicate that LOH in the 
tumor microenvironment is regulated 
in a cell-specific manner and that the 
rate of LOH depends on the stage 
of tumor progression and proximity 
of the stroma to the tumor mass. In 
addition to mutation and LOH, there 
are epigenetic changes in the tumor 
microenvironment that clearly influ-
ence tumor progression. Epigenetic 
modification of gene expression is 
also dependent on the proximity to 
the tumor mass, stage of progression, 
and cell type used for analysis (Hu et 
al., 2005).
It is not known whether the selective 
pressure placed on stromal cells by 
the epithelium as described by Hill et 
al. (2005) occurs in all tumor microen-
vironments or whether the specific lin-
eage of the fibroblast subpopulations 
(e.g., prostate fibroblasts versus mam-
mary-gland fibroblasts) influences 
the ability to respond to this type of 
selective pressure. It will be instruc-
tive in future studies to compare the 
current data of Hill et al. (2005) with 
those from other cancer models This 
should help to determine whether this 
newly described selective evolution of 
p53-deficient stroma is a general char-
acteristic that can help to explain the 
prevalence of this and other common 
mutations in human cancer.
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